Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 29
States / cities: Escondido, California • Greenbrae, California • Los Angeles, California + 25 more

Conditions: Diabetes
Interventions: Cannabidiol (CBD) powder formulation, Matching Placebo Cannabidiol (CBD) powder formulation; Dietary Supplement
Lead sponsor: Christopher Bell; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Chronic Hepatitis C
Interventions: Daclatasvir, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Anaheim, California • Cypress, California • New Haven, Connecticut + 4 more

Conditions: Pain
Interventions: SRP-3D (diethylamide), Placebo; Drug
Lead sponsor: South Rampart Pharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Adverse Childhood Experiences, Endothelial Dysfunction
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Iowa City, Iowa • Madison, Wisconsin

Conditions: Alcohol Dependence
Interventions: Acamprosate (Campral); Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Milwaukee, Wisconsin

Conditions: Covid19
Interventions: BGB-DXP593, Placebo; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: DeLand, Florida • Hollywood, Florida • Miami, Florida + 5 more

Conditions: Type I Diabetes
Interventions: OPT101, OPT101 Placebo to Match (PTM); Drug · Other
Lead sponsor: Op-T LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 2 more

Conditions: Prostate Cancer
Interventions: Orteronel, Orteronel Placebo, Prednisone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Diabetes Mellitus Type 2
Interventions: EGT0001442, Placebo capsules to match EGT0001442; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Birmingham, Alabama • National City, California • Denver, Colorado + 4 more

Conditions: Irritable Bowel Syndrome With Constipation
Interventions: Linaclotide, Matching Placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 71
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more

Conditions: Opioid Use Disorders
Interventions: CAM2038 SC injection, SL BPN/NX tabs, placebo SC injections, SL placebo tablets; Drug
Lead sponsor: Braeburn Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 36
States / cities: Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more

Conditions: Irritable Bowel Syndrome
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 232
States / cities: Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 189 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: AMG 609, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Chandler, Arizona • Chula Vista, California • Montclair, California + 5 more

Conditions: 22q11 Deletion Syndrome
Interventions: NB-001, Placebo; Drug · Other
Lead sponsor: Nobias Therapeutics, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Crohn's Disease
Interventions: Placebo Comparator, Rifaximin; Drug
Lead sponsor: Scott Lee; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes Mellitus, Glucose Metabolism Disorders
Interventions: Diazoxide, Nicotinic acid, Placebo; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Acne Vulgaris
Interventions: 50 mg P005672-HCl, Placebo, 100 mg P005672-HCl; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 38
States / cities: Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 34 more

Conditions: Lumbosacral Radiculopathy
Interventions: z160, Placebo; Drug
Lead sponsor: Zalicus; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Huntsville, Alabama • Peoria, Arizona • Anaheim, California + 19 more

Conditions: Alopecia Areata
Interventions: PF-06651600, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 23
States / cities: Huntington Beach, California • Irvine, California • Boca Raton, Florida + 17 more

Conditions: Phenylketonuria
Interventions: JNT-517 Suspension, Placebo Suspension, JNT-517 Tablet, Placebo Tablet; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 11
States / cities: Gainesville, Florida • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Lyme Disease
Interventions: mRNA-1975, mRNA-1982, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 807 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 20
States / cities: Milford, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 17 more

Conditions: Lyme Disease
Interventions: TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High Dose, Placebo; Drug
Lead sponsor: Tarsus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 722 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 19
States / cities: Pikesville, Maryland • Brookline, Massachusetts • Fall River, Massachusetts + 16 more

Conditions: Photosensitive Epilepsy
Interventions: Placebo, E2082; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Little Rock, Arkansas • Boise, Idaho • Baltimore, Maryland + 2 more

Search by objective public record fields.

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Influence of Cannabidiol on Glucose Tolerance and The Gut Microbiota

A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)

ACEs, SIRT1, and Premature Vascular Aging in Humans

Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

Induction of Clinical Response Using Rifaximin in Crohn's Disease

Regulation of Endogenous Glucose Production by Central KATP Channels

Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure

A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy